Oblenio Bio raises $62M to take T-cell engager into autoimmune disease
What's the deal? Oblenio Bio has raised $62 million in a Series B round led by Pfizer VenturesDealroom has a profile for this one. Try Dealroom →.
The biotech will use the funds to advance a trispecific T-cell engager (TCE) aimed at treating autoimmune diseases.
Why now? T-cell engagers, long used in cancer, are increasingly being tested against autoimmune conditions. Pfizer Ventures' backing signals confidence in that shift, giving Oblenio capital to push its lead candidate forward.
What could go wrong? Trispecific engagers are complex molecules, and translating early science into safe, effective therapies is far from guaranteed.
PfizerDealroom has a profile for this one. Try Dealroom → itself knows the risks of betting on novel platforms; its $43 billion Seagen acquisition has soured as an antibody-drug conjugate failed in late-stage lung cancer.
The signal: Pfizer Ventures leading an early-stage company's Series B underlines how pharma venture arms are positioning around the shift of T-cell engagers from oncology into autoimmune disease, where Oblenio is betting its trispecific antibody can stand out. With its corporate parent's $43 billion Seagen deal souring, Pfizer's appetite for novel platforms like this one looks undimmed.
Read more: Endpoints News
Image credit: National Institutes of Health (NIH)
